Abstract
Understanding the pharmacogenetic basis of developing iatrogenic disorders such as Tardive Dyskinesia (TD) has significant clinical implications. CYP1A2, an inducible gene of the cytochrome P450 family of genes, has been suggested to contribute to the metabolism of typical antipsychotics in subjects with schizophrenia on long-term treatment, and has been considered as a potential candidate gene for development of TD. In this study, we have investigated the significance of CYP1A2 gene polymorphisms in TD susceptibility among chronic schizophrenia sufferers (n=335) from north India. TD was diagnosed in ∼29% (96/335) of these subjects. Of the 96 TD positives, 28 had been treated with typical antipsychotics alone, 23 with atypical antipsychotics alone and 45 patients had received both classes of drugs during the course of their illness. Out of the six SNPs tested, CYP1A2*2, *4, *5, *6 were found to be monomorphic in our population. CYP1A2*1C and CYP1A2*1F were polymorphic and were analyzed in the study sample. Since these two allelic variants lead to lesser inducibility among smokers, the smoking status of TD patients was also considered for all subsequent analysis. We observed increased severity of TD among TD-Y smokers, who were carriers of CYP1A2*1C (G>A) variant allele and had received only typical antipsychotic drugs (F(1,8)=9.203, P=0.016). No significant association of CYP1A2*1F with TD was observed irrespective of the class of drug they received or their smoking status. However, we found a significant association of CYP1A2*1F with schizophrenia (χ2=6.572, df=2, P=0.037).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Yassa R, Ananth J . Familial Tardive dyskinesia. Am J Psychiatry 1981; 138: 1618–1619.
Muller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T et al. Familial occurrence of Tardive dyskinesia. Acta Psychiatr Scand 2001; 104: 375–379.
Kane JM, Smith JM . Tardive Dyskinesia: prevalence and risk factors 1959 to 1979. Arch Gen Pscychiaty 1982; 39: 473–481.
Bergen J, Kitchin R, Berry G . Predictors of the course of Tardive Dyskinesia in patients receiving neuroleptics. Biol Psychiatry 1992; 32: 580–594.
Jeste DW, Wyatt RJ . Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor sensitivity? J Clin Psychiatry 1981; 42: 455–457.
Casey DE, Geralch J, Bjondal N . Levodopa and receptor sensitivity modification in tardive dyskinesia. Psychopharmacology 1982; 78: 89–92.
Geralch J, Casey DE . Sulpiride in tardive dyskinesia. Acta Psychiatr Scand 1984; 311: 93–102.
Mehsul CK, Casey DE . Regional, reversible ultrastructural changesin rat brain with chronic neuroleptic treatment. Brain Res 1989; 489: 338–346.
Gordon JH, Fields JZ . A permanent dopamine receptor upregulation in the ovariectomized rat. Pharmacol Biochem Behav 1989; 33: 123–125.
Basile VS, Masellis M, Potkin SG, Kennedy JL . Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 2002; 11: 2517–2530.
Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R et al. Pharmacogenetics of Tardive Dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27: 105–118.
Shimada T, Yamazaki H, Mimura M, Inui Y, Gungerich FP . Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Ther 1994; 270: 414–423.
Arthur H, Dahl ML, Siwers B, Sjoqvist F . Polymorphic drug metabolism in schizophrenia patients with tardive dyskinesia. J Clin Psychpharmacol 1995; 15: 211–216.
Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR . Antipsychotic induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 1997; 170: 23–26.
Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA et al. A functional polymorphism of the cytochrome P450 1A2(CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000; 5: 410–417.
Smith SS, Fiore MC . The epidemiology of tobacco use, dependence and cessation in the United States. Primary Care 1999; 26: 433–461.
Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamakati T . Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999; 125: 803–808.
Sachse C, Brockmoller J, Bauer S, Roots I . Functional significance of a C>A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445–449.
Guy W (ed). Early Clinical Drug Evaluation Unit b Assessment Manual. US Department of health and human services, National Institute of Mental Health (NIMH): Rockville, Maryland 1976.
Schultze TG, Schumacher J, Muller DJ, Krauss H, Alfter D, Maroldt A et al. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001; 105: 498–501.
Chong S, Tan E, Tan CH, Mythily . Smoking and Tardive Dyskinesia: lack of involvement of the CYP1A2 gene. J Psychiatry Neurosci 2003; 28: 185–189.
Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999; 21: 17–27.
Kane JM . Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry 1992; 160: 41–45.
Yassa R, Jeste DV . Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992; 18: 701–715.
Chevalier D, Cauffiez C, Allorge D, Lo-Guidice JM, Lhermitte M, Lafitte JJ et al. Five novel natural allelic variants – 951 A>C, 1042 G>A (D348N), 1156A>T (I386F), 1217 G>A (C406Y) and 1291 C>T (C4341Y) – of the mutation in a French Caucasian population. Hum Mutat 2001; 17: 355–360.
Nebert DW . Polymorphism in drug metabolizing enzymes: what is their clinical relevance and why do they exists? Am J Hum Genet 1997; 60: 265–271.
Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S . Human CYP1A2: sequence, gene structure, comparison with mouse and rat orthologous gene, and differences in liver mRNA expression. Mol Endocrinol 1989; 3: 1399–1408.
Pickwell GV, Shih H, Quattrochi LC . Interaction of upstream stimulatory factor proteins with an E-box located within the human CYP1A2 5′-flanking gene contributes to basal transcriptional gene activation. Biochem Pharmacol 2003; 65: 1087–1096.
Hamdy SI, Hiratsuka M, Narahara K, Endo N, El-Enany M, Moursi N et al. Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population. Br J Clin Pharmacol 2003; 55: 321–324.
Coon H, Jensen S, Holik J, Hoff M, Myles-Worsley M, Reimherr F et al. Genomic scan for genes predisposing to schizophrenia. Am J Med Genet 1994; 54: 59–71.
Kaufman CA, Suarez B, Malaspina D, Pepel J, Svarakic D, Meyer J et al. NIMH genetics initiative millenium schizophrenia consortium: linkage analysis of African American pedigrees. Am J Med Genet 1998; 88: 29–33.
Stober G, Saar K, Ruschendorf F, Meyer J, Nurnberg G, Jatzke S et al. Splitting schizophrenia: periodic catatonia - susceptibility locus on chromosome 15q15. Am J Hum Genet 2000; 67: 1201–1207.
Freedman A, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. PNAS 1997; 94: 587–592.
Riley B P, Makoff A, Mogudi-Carter M, Jenkins T, Williamson RD, Murray R . Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern Africal Bantu families. Am J Med Genet 2000; 96: 196–201.
Liu C, Hwo H, Lin M, Ou-yang W, Lee S, Fann C et al. Suggestive evidence for linkage of schizophrenia markers at chromosome 15q13–14 in Taiwanese families. Am J Med Genet 2000; 105: 658–661.
Morse DC, Steim AP, Thomas PE, Lowndess HE . Distribution and induction of cytochrome P450 1A1 and 1A2 in rat brain. Toxicol Appl Pharmacol 1998; 152: 232–239.
Nurnberger Jr JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994; 5: 849–859.
Deshpande SN, Mathur MNL, Das SK, Bhatia T, Sharma SD, Nimgaonkar VL . A hindi version of the diagnostic interview for genetic studies. Schizophr Bull 1998; 24: 489–493.
Schooler NR, Kane JM . Research diagnoses for tardive Dyskinesia. Arch Gen Prychiatry 1982; 39: 486–487.
Simpson GM, Angus JWS . Drug-induced extrapyramidal disorder – a rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 20–27.
Sambrook J, Fritsch EE, Maniatis T . Molecular Cloning: A Laboratory Manual. 2nd edn, Cold Spring Harbor Laboratory press: Cold Spring Harbor, NY 1989.
Gordon D, Finch SJ, Nothnagel M, Ott J . Power and sample size calculations for case–control genetic association tests when errors present: application to single nucleotide polymorphisms. Hum Heredity 2002; 54: 22–33.
Gordon D, Levenstien MA, Finch SJ, Ott J . Errors and linkage disequilibrium interact multiplicatively when computing sample sizes for genetic case–control association studies. Pacific Symposium on Biocomputing. 2003, pp 490–501.
Stephens M, Smith NJ, Donnelly P . A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978–989.
Stephens M, Donnelly P . Comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162–1169.
Sham PC, Curtis D . Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995; 59: 97–105.
Acknowledgements
This work is supported by Indo-Israel grants BT/IC-2/Israel/Deshpande/2002 and BT/IC-2/00/Smita/99 (to SND, BKT, BL); Department of Biotechnology (Govt of India) Grant BT/PR2425/Med 13/089/2001 (to BKT and SND); Indo-US Grant N-443-645 (to VLN, BKT, SND); and a research fellowship from the University Grants Commission, New Delhi to AKT.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tiwari, A., Deshpande, S., Rao, A. et al. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J 5, 60–69 (2005). https://doi.org/10.1038/sj.tpj.6500282
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.tpj.6500282
Keywords
This article is cited by
-
Antipsychotikainduzierte tardive Syndrome
neuropsychiatrie (2016)
-
Prenatal Exposure of Cypermethrin Induces Similar Alterations in Xenobiotic-Metabolizing Cytochrome P450s and Rate-Limiting Enzymes of Neurotransmitter Synthesis in Brain Regions of Rat Offsprings During Postnatal Development
Molecular Neurobiology (2016)
-
CYP1A2polymorphism −1545C > T (rs2470890) is associated with increased side effects to clozapine
BMC Psychiatry (2014)
-
Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses
The Pharmacogenomics Journal (2011)
-
Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions
Molecular Psychiatry (2008)